from IPSEN (EPA:IPN)
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
Press Release
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
- 14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement disorders
- Interim data from the ongoing EPITOME trial1 showed that 45.7% of stroke survivors with paresis developed post-stroke spasticity within 1 year
- <1% of stroke survivors receive BoNT-A treatment for spasticity in routine practice2
PARIS, FRANCE, 14 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of 14 across multiple neurological conditions at the TOXINS 2026 conference (14-17 January) in Madrid, Spain. Data presented highlighted the depth and diversity of evidence across multiple movement disorders — including post‑stroke spasticity, cervical dystonia and blepharospasm, adding to the available evidence of Dysport®(abobotulinumtoxinA) in patient care – alongside new indications under evaluation.
An interim analysis from the ongoing EPITOME study will be presented. EPITOME is a multi-country epidemiologic study following adults aged 18–85 after their first stroke, to better understand how often post-stroke spasticity (PSS) occurs and to better improve early identification. The study focuses on a Post-stroke Spasticity Monitoring Questionnaire, a remote monitoring tool designed to help clinicians detect early signs of spasticity.
PSS can develop following a stroke and often goes undiagnosed, delaying treatment and limiting recovery. Remote monitoring can help clinicians act sooner, improving the potential for swift rehabilitation and better quality of life for patients. In this interim analysis, 45.7% of stroke survivors with paresis developed spasticity within 1 year of their stroke vs previously documented 39.5%,3 reinforcing the value of monitoring within this period. Previously published real-world evidence and quality of life insights reinforce the existing care gap, with <1% of stroke survivors receiving BoNT-A treatment for spasticity in routine practice.2
“We are proud to present this breadth of data which underscores our mission to bring solutions and address care gaps for people living with a broad range of neurological conditions,” said Sandra Silvestri, MD, PhD, Executive Vice President, Chief Medical Officer, Ipsen. “The EPITOME study is one example of this, focused on providing a standardized and best-practice follow-up to ensure people living after a stroke receive the care they deserve.”
Complete list of Ipsen presentations at TOXINS 2026:
| Lead author | Abstract title |
|---|---|
| Esquenazi, A. | Poster presentation: Regional differences in use of injection guidance and goal attainment following repeat abobotulinumtoxinA injections: Subgroup analysis of the AboLiSh observational study. |
| Ashford, S. | Poster presentation: Quality of life (QoL) improvements in patients with leg spasticity following treatment with abobotulinumtoxinA: Assessment using a disease-specific and a generic QoL instrument. |
| Wainberg, M. | Poster presentation: Persistence with botulinum neurotoxin type A and factors associated with discontinuation: A retrospective cohort study. |
| Patel, A. | Poster presentation: Effect of early use of botulinum toxin A on goal attainment in post-stroke spasticity. |
| Wilkie, A. | Poster presentation: Mapping the journey and experience of people living with post-stroke spasticity |
| Turner-Stokes, L. | Poster presentation: Longitudinal goal attainment across four consecutive botulinum neurotoxin treatment cycles in adults with upper limb spasticity. |
| Schramm, A. | Poster presentation: Interim analysis of the non-interventional SMART study on the effectiveness and safety of abobotulinumtoxinA injections in everyday practice in patients with upper limb spasticity after stroke. |
| Palmcrantz S. | Poster presentation: Identifying post-stroke spasticity in Swedish healthcare registers: A real-world analysis. |
| Bensmail, D. | Poster presentation: Real-world use of botulinum neurotoxin type A in post-stroke spasticity between 2015 and 2023: Insights from France. |
| Degos, B. | Poster presentation: Patterns of botulinum toxin type A (BoNT-A) treatment in parkinsonian syndromes: A nationwide French study (2015-2023). |
| Simonetta‑Moreau, M. | Poster presentation: Real-world use of botulinum toxin type A (BoNT-A) for hyperkinetic movement disorders: Insights from a French nationwide registry (2015-2023). |
| Ailani, J. | Poster presentation: Methodology of the BEOND Phase 3 clinical trials for evaluating abobotulinumtoxinA for migraine prevention. |
| Robinson, A. | Oral presentation Friday 16 January 15:00-15:10CET and poster presentation: Utilizing a novel botulinum toxin to investigate intracellular trafficking. |
| Zorowitz, R. | Poster presentation: Sensitivity and specificity of the Post-stroke Spasticity Monitoring Questionnaire (PSMQ) for remote monitoring of spasticity development: Interim analysis from an ongoing epidemiology study. |
About Dysport
Dysport® (abobotulinumtoxinA) is an injectable form of a botulinum neurotoxin type A (BoNT-A) product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. AbobotulinumtoxinA has marketing authorization in approximately 90 countries, more than 30 years of clinical experience and >18 million treatment years of patient experience.
The detailed recommendations for the use of Dysport are described in the Summary of Product Characteristics (SmPC) for Dysport (300 units) Powder and Dysport (500 units) Powder, and the U.S. Prescribing Information (PI).
NOTE: Dysport® labels and approved indications may vary from country to country.
About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit www.Ipsen.com.
Ipsen Contacts
Investors
Henry Wheeler henry.wheeler@ipsen.com +33 7 66 47 11 49
Khalid Deojee khalid.deojee@ipsen.com +33 6 66 01 95 26
Media
Sally Bain sally.bain@ipsen.com +1 857 320 0517
Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96
Disclaimers and/or forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward